Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck

James Y. Suen, Stephen P. Richman, Robert B. Livingston, Evan M. Hersh, Robert Craig, Kenneth Tonymon

Research output: Contribution to journalArticle

12 Scopus citations


One hundred patients with advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck were treated with chemotherapy and BCG as adjuvant immunotherapy. The overall response rate was 35 per cent, and the median duration of response was seventeen weeks. BCG does not prolong duration of remission or survival time.

Original languageEnglish (US)
Pages (from-to)474-478
Number of pages5
JournalThe American Journal of Surgery
Issue number4
StatePublished - Oct 1977


ASJC Scopus subject areas

  • Surgery

Cite this